76 related articles for article (PubMed ID: 19046724)
1. The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer.
Montagnani A; Gonnelli S; Cadirni A; Caffarelli C; Del Santo K; Pieropan C; Campagna MS; Montomoli M; Petrioli R; Nuti R
Eur J Intern Med; 2008 Dec; 19(8):592-7. PubMed ID: 19046724
[TBL] [Abstract][Full Text] [Related]
2. Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy.
Markopoulos C; Dafni U; Misitzis J; Zobolas V; Tzoracoleftherakis E; Koukouras D; Xepapadakis G; Papadiamantis J; Venizelos B; Antonopoulou Z; Gogas H
Breast Cancer Res; 2009; 11(3):R35. PubMed ID: 19531217
[TBL] [Abstract][Full Text] [Related]
3. Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.
Szijgyarto Z; Flach KD; Opdam M; Palmieri C; Linn SC; Wesseling J; Ali S; Bliss JM; Cheang MCU; Zwart W; Coombes RC
Breast Cancer Res Treat; 2019 May; 175(1):149-163. PubMed ID: 30680659
[TBL] [Abstract][Full Text] [Related]
4. Lipid profiles within the SABRE trial of anastrozole with and without risedronate.
Van Poznak C; Makris A; Clack G; Barlow DH; Eastell R
Breast Cancer Res Treat; 2012 Aug; 134(3):1141-7. PubMed ID: 22763465
[TBL] [Abstract][Full Text] [Related]
5. Exemestane in the adjuvant treatment of breast cancer in postmenopausal women.
Kittaneh M; Glück S
Breast Cancer (Auckl); 2011; 5():209-26. PubMed ID: 22084574
[TBL] [Abstract][Full Text] [Related]
6. Lipid changes during endocrine therapy in early-stage breast cancer patients: A real-world study.
Li Y; Deng Z; Wang Y; Shen S
Lipids Health Dis; 2024 Jan; 23(1):9. PubMed ID: 38191454
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen- and Triptorelin-Induced Major Hypertriglyceridemia: A Case Report.
Moussaoui W; Lahmamssi FZ; Aynaou H; Salhi H; El Ouahabi H
Cureus; 2024 Feb; 16(2):e53779. PubMed ID: 38469007
[TBL] [Abstract][Full Text] [Related]
8. Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis.
Bérczi B; Farkas N; Hegyi P; Tóth B; Csupor D; Németh B; Lukács A; Czumbel LM; Kerémi B; Kiss I; Szabó A; Varga G; Gerber G; Gyöngyi Z
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38542042
[No Abstract] [Full Text] [Related]
9. Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy.
Thomas NS; Scalzo RL; Wellberg EA
Nat Rev Endocrinol; 2024 Jan; 20(1):16-26. PubMed ID: 37783846
[TBL] [Abstract][Full Text] [Related]
10. Risks of Aromatase Inhibitor-Related Cardiotoxicity in Patients with Breast Cancer in Asia.
Chang WT; Chen PW; Lin HW; Kuo YH; Lin SH; Li YH
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158776
[TBL] [Abstract][Full Text] [Related]
11. Aging, obesity, sarcopenia and the effect of diet and exercise intervention.
Colleluori G; Villareal DT
Exp Gerontol; 2021 Nov; 155():111561. PubMed ID: 34562568
[TBL] [Abstract][Full Text] [Related]
12. Mammary gland adipocytes in lactation cycle, obesity and breast cancer.
Colleluori G; Perugini J; Barbatelli G; Cinti S
Rev Endocr Metab Disord; 2021 Jun; 22(2):241-255. PubMed ID: 33751362
[TBL] [Abstract][Full Text] [Related]
13. Aromatase Inhibitors Plus Weight Loss Improves the Hormonal Profile of Obese Hypogonadal Men Without Causing Major Side Effects.
Colleluori G; Chen R; Turin CG; Vigevano F; Qualls C; Johnson B; Mediwala S; Villareal DT; Armamento-Villareal R
Front Endocrinol (Lausanne); 2020; 11():277. PubMed ID: 32499757
[No Abstract] [Full Text] [Related]
14. Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety.
Gatti-Mays ME; Venzon D; Galbo CE; Singer A; Reynolds J; Makariou E; Kallakury B; Heckman-Stoddard BM; Korde L; Isaacs C; Warren R; Gallagher A; Eng-Wong J
Cancer Prev Res (Phila); 2016 Mar; 9(3):225-33. PubMed ID: 26758879
[TBL] [Abstract][Full Text] [Related]
15. Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.
Santa-Maria CA; Blackford A; Nguyen AT; Skaar TC; Philips S; Oesterreich S; Rae JM; Desta Z; Robarge J; Henry NL; Storniolo AM; Hayes DF; Blumenthal RS; Ouyang P; Post WS; Flockhart DA; Stearns V;
Clin Cancer Res; 2016 Mar; 22(6):1395-402. PubMed ID: 26463708
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.
Napoli N; Rastelli A; Ma C; Colleluori G; Vattikuti S; Armamento-Villareal R
Pharmacogenet Genomics; 2015 Aug; 25(8):377-81. PubMed ID: 26049585
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant tamoxifen influences the lipid profile in breast cancer patients.
Lin C; Chen LS; Kuo SJ; Chen DR
Breast Care (Basel); 2014 Feb; 9(1):35-9. PubMed ID: 24803885
[TBL] [Abstract][Full Text] [Related]
18. The muscle mass, omega-3, diet, exercise and lifestyle (MODEL) study - a randomised controlled trial for women who have completed breast cancer treatment.
McDonald C; Bauer J; Capra S; Coll J
BMC Cancer; 2014 Apr; 14():264. PubMed ID: 24739260
[TBL] [Abstract][Full Text] [Related]
19. Muscle function and omega-3 fatty acids in the prediction of lean body mass after breast cancer treatment.
McDonald C; Bauer J; Capra S; Waterhouse M
Springerplus; 2013; 2():681. PubMed ID: 24404435
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
